Correlation Between Base Excess in Patients Upon Admission to the ICU and Platelet Count Trend in the Following Days (BE-Platelet)

March 31, 2025 updated by: Irena Grad, University Medical Centre Ljubljana

Correlation Between the Severity of Metabolic Acidosis in Patients on Admission to the ICU and Platelet Count Trend in the Following Days

Several studies have revealed that a relative platelet count decline in patients after their admission to the intensive care unit (ICU) is a very reliable marker of the severity of their sickness. ICU patients with a greater platelet count decline after their admission to the ICU have generally worse outcome. Investigators assume that a quick appearance of a deep metabolic acidosis, which commonly occurs in critically ill, has an important role in pathogenesis of relative platelet count decline. To evaluate this, correlation of metabolic acidosis severity in participants upon admission to the ICU with platelet count decline in 2 days, following admission, was investigated with a retrospective observational study, analysing all participants, admitted to the ICU in one year period (in 2020).

As a measurement of metabolic acidosis severity, investigators took base excess (BE) value (expressed in mmol/L) from arterial blood gas analysis with lowest pH in participants in around admission time (in a period from 24 hours before to 24 hours after their admission to the ICU). To calculate relative platelet count decline in 2 days after admission to the ICU, investigators took platelet count on admission to the ICU (P0) and lowest platelet count on day 2 after the patient's admission (P2). Following formula was used to calculate relative platelet count decline in 2 days after ICU admission (delta P): delta P = (P2-P0)/P0 x 100 (expressed in %). More negative values of delta P represent larger relative platelet count decline.

The main interest of the study was if BE value correlates with delta P. Investigators assumed that participants with a more severe metabolic acidosis upon admission to the ICU (represented with more negative BE value) would tend to have a larger relative platelet count decline in 2 days, following admission to the ICU (represented with more negative value of delta P).

Pearson correlation was used to evaluate correlation between BE and delta P.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The aim of the study was to answer the question, if metabolic acidosis severity in participants upon admission to the ICU correlatets with platelet count decline in days, following admission.

Investigators conducted this study at the Department of Anesthesiology and Surgical Intensive Care at University Medical Centre Ljubljana. The study included all participants, admitted to the ICU in a one-year period (in 2020; from 1st January to 31st December 2020). From the electronic recordings of the department (Hospital Information System BIRPIS21), investigators obtained the following data of each participant: age, gender, lowest pH in arterial blood gas analysis in around admission time with corresponding bicarbonate concentration [HCO3-] and BE value, platelet count on admission (P0), and lowest platelet count on second day after ICU admission (P2).

As a measurement of metabolic acidosis severity, investigators took the BE value of arterial blood gas analysis with the lowest pH from the range of 24 hours before to 24 hours after ICU admission. To calculate relative platelet count decline in 2 days after ICU admission (delta P), the following formula was used: delta P = (P2-P0)/P0 x 100.

Participants who died before the second day after ICU admission or participants whose demanded laboratory findings were for some other reasons lacking (arterial blood gas analysis or platelet count on admission or platelet count on second day after ICU admission), were excluded from final analysis of correlation between BE and delta P.

Pearson's correlation coefficient (r) with 95% confidence interval (CI) was used to estimate the association between BE and delta P.

Study Type

Observational

Enrollment (Actual)

484

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Slovenia
      • Ljubljana, Slovenia, 1000
        • University Medical Centre Ljubljana, Zaloška cesta 7, 1000 Ljubljana, Slovenia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Study has been conducted at the Department of Anaesthesiology and Surgical Intensive Care at University Medical Centre Ljubljana. All participants, admitted to the ICU of Department of Anaesthesiology and Surgical Intensive Care in 2020 were included.

Description

Inclusion Criteria:

  • Admitted to the ICU department in a 1 year period (from 1st January to 31th December 2020)

Exclusion Criteria:

  • Lacking blood gas analysis data on admission
  • Incomplete platelet count data (lacking platelet count on admission to the ICU and day 2 after the admission)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Relative platelet count decline in participants from admission to the ICU to their second day after ICU admission
Time Frame: From admission to the ICU (base line) and 2 days following admission

In this observational study relative platelet count decline in participants from admission to the ICU to their second day after the admission to the ICU was measured (with the aim to analyse correlation between metabolic acidosis severity in participants upon admission to the ICU and platelet count trend in participants in the following 2 days).

Platelet count value in participants upon admission to the ICU (P0) and lowest platelet count value on day 2 after the admission to the ICU (P2) were used to calculate relative platelet count decline in 2 days after ICU admission (delta P), using formula: delta P = (P2-P0)/P0 x 100 (delta P expressed in %).
From admission to the ICU (base line) and 2 days following admission

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Medical Centre Ljubljana

Investigators

  • Study Chair: Primož Gradišek, MD, PhD, Prof., Department of Anaesthesiology and Surgical Intensive Care

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 11, 2024

Primary Completion (Actual)

February 11, 2024

Study Completion (Actual)

February 14, 2024

Study Registration Dates

First Submitted

March 22, 2025

First Submitted That Met QC Criteria

March 31, 2025

First Posted (Actual)

April 3, 2025

Study Record Updates

Last Update Posted (Actual)

April 3, 2025

Last Update Submitted That Met QC Criteria

March 31, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UMCLj-BE-Platelet
  • Irena Grad (Other Identifier: UMCLjubljana)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All collected IPD

IPD Sharing Time Frame

Beginning with publication of results with no end date.

IPD Sharing Access Criteria

After publication of results all IPD data of the study can be shared on request on email of investigator: irena.grad@gmail.com

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metabolic Acidosis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe